Venus Remedies secures renewed EU GMP certification for its manufacturing facility, enabling expansion in European and global ...

Imexpharm Corporation has announced its 2024 financial results with net revenue reaching VND2,205 billion, up 10.6 percent ...

Pharma major Venus Remedies on Tuesday said it has secured renewal of European Good Manufacturing Practices (EU-GMP) certification by Infarmed, the National Authority of Medicines and Health Products ...

The rise in Venus Remedies share price came after the company announced the renewal of its European GMP certification by ...

Venues remedies rallied 5.30% to Rs 310.95 after the company successfully renewed its European good manufacturing practices (GMP) certification by infarmed, the national health authority of Medicines ...

Imexpharm Corporation reported VND2,205 billion (US$87.3 million) in net revenue for 2024, marking a 10.6% year-on-year increase.

Venus Remedies secures EU GMP renewal from Infarmed, strengthens European market presence: Our Bureau, Bengaluru Wednesday, January 22, 2025, 15:30 Hrs [IST] Venus Remedies has an ...

"Since our first EU GMP certification in 2007, we have not only maintained but strengthened our foothold in the European market. This latest certification renewal enables us to leverage our ...

The certification covers the company’s manufacturing facility for cephalosporin, carbapenem, and lyophilized injectable ...

HYTN will endeavour to amend its licenses and/or certificates, establish a stability program, and implement GMP-compliant processes tailored for vape cartridge production.

VANCOUVER, British Columbia, Jan. 21, 2025 (GLOBE NEWSWIRE) -- (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a company specializing in pharmaceutical-grade cannabis manufacturing ...

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces today the launch of the company's first German-cultivated medical cannabis product, ...